Market Currents
Biogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results...
-
Wednesday, September 26, 2012, 8:23 AM ETBiogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results from a study of their clotting factor candidate for patients with hemophilia B. The recombinant Factor IX Fc fusion protein was "generally well tolerated" and offers a more long-lasting treatment than current therapies requiring up to three intravenous injections a week. BIIB +2.4% premarket.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
